Search hospitals > Indiana > Indianapolis
IU Health Methodist Hospital
Claim this profileIndianapolis, Indiana 46202
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in Heart Failure
Conducts research for Breast Cancer
Conducts research for Cancer
Conducts research for Wounds and Injuries
229 reported clinical trials
28 medical researchers
Summary
IU Health Methodist Hospital is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Human Immunodeficiency Virus Infection, Heart Failure, Breast Cancer, Cancer, Wounds and Injuries and other specialties. IU Health Methodist Hospital is involved with conducting 229 clinical trials across 315 conditions. There are 28 research doctors associated with this hospital, such as Kathy Miller, MD, Gayle Gordillo, MD, Rafat Abonour, MD, and Greg Durm.Top PIs
Kathy Miller, MDIndiana University/Melvin and Bren Simon Cancer Center8 years of reported clinical research
Expert in Breast Cancer
Studies Cancer
17 reported clinical trials
55 drugs studied
Gayle Gordillo, MDIU Health Methodist Hospital4 years of reported clinical research
Studies Wounds and Injuries
Studies Leg Ulcer
9 reported clinical trials
13 drugs studied
Rafat Abonour, MDIndiana University/Melvin and Bren Simon Cancer Center6 years of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
7 reported clinical trials
11 drugs studied
Greg DurmIndiana University/Melvin and Bren Simon Cancer Center5 years of reported clinical research
Studies Cancer
Studies Lung Cancer
7 reported clinical trials
14 drugs studied
Clinical Trials running at IU Health Methodist Hospital
Multiple Myeloma
Squamous Cell Carcinoma
Oropharyngeal Carcinoma
Breast Cancer
Laryngeal Cancer
Kidney Stones
Heart Failure
Plasma Cell Neoplasms
Meningioma
Cardiac Arrest
Lenalidomide + Dexamethasone +/- Daratumumab
for Multiple Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Recruiting2 awards Phase 312 criteria
Lenalidomide +/- Daratumumab
for Multiple Myeloma
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.
Recruiting2 awards Phase 317 criteria
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at IU Health Methodist Hospital?
IU Health Methodist Hospital is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Human Immunodeficiency Virus Infection, Heart Failure, Breast Cancer, Cancer, Wounds and Injuries and other specialties. IU Health Methodist Hospital is involved with conducting 229 clinical trials across 315 conditions. There are 28 research doctors associated with this hospital, such as Kathy Miller, MD, Gayle Gordillo, MD, Rafat Abonour, MD, and Greg Durm.